Pluri Inc. Secures Additional $1.4 Million Funding from U.S. NIH for Acute Radiation Syndrome Treatment Contract

HAIFA, Israel, June 06, 2024 – Pluri Inc. (PLUR), an innovator in the field of biotechnological cell therapies, has revealed a significant development in its contractual relationship with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The company has been granted a substantial second-year budget, totaling $1.4 million, for the continued research and development of PLX-R18, its cellular therapy designed to treat Acute Radiation Syndrome (ARS).

Progress in PLX-R18 ARS Treatment Research

PLX-R18 is one of Pluri’s flagship therapies, which has shown promise in the effective management and treatment of ARS, a serious illness caused by high doses of radiation exposure. By securing an additional year of funding, Pluri Inc. [PLUR] is poised to build upon its first year’s advancements in developing an efficient and possibly life-saving treatment for those affected by radiation-related health crises.

Details of the NIH’s Continued Support

Upon the successful completion of the first year’s objectives, the NIAID’s decision to exercise the option for further funding emphasizes the potential that PLX-R18 has shown in the realm of ARS treatment. This financial injection from the U.S. government not only underscores the critical importance of developing treatments for ARS but also reaffirms the confidence in the scientific approach embraced by Pluri Inc. [PLUR].

Impact on Pluri Inc. and Its Stakeholders

The continued partnership and financial backing from the U.S. NIH demonstrates the agency’s commitment to addressing national health emergencies through cutting-edge medical research and development. For Pluri Inc. [PLUR], this serves as a catalyst for more robust research endeavors and cements its position as a leading biotech entity in the ARS therapeutic landscape. Shareholders and potential investors in Pluri Inc. might regard this news as an affirmation of the company's growth trajectory and its potential for future successes.

Pluri, NIH, Funding, Biotechnology, Therapy, PLUR, Investment, Healthcare